Encision (ECIA) 10-K 23 Jun 21 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2021	May 28, 2021	Sep. 28, 2020
Document and Entity Information
Entity Registrant Name	ENCISION INC
Entity Central Index Key	0000930775
Document Type	10-K
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity File Number	001-11789
Entity Incorporation, State Country Code	CO
Entity Interactive Data Current	Yes
Entity Public Float			$ 2,933,441
Entity Common Stock, Shares Outstanding		11,582,641
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
ICFR Auditor Attestation Flag	false

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Current assets:
Cash	$ 1,474,339	$ 385,132
Accounts receivable, net of allowance for doubtful accounts of $35,000 at March 31, 2021 and $58,000 at March 31, 2020	1,024,370	881,194
Inventories, net of reserve for obsolescence of $70,000 at March 31, 2021 and $39,000 at March 31, 2020	1,445,134	1,625,901
Prepaid expenses and other assets	154,151	72,639
Total current assets	4,097,994	2,964,766
Equipment:
Furniture, fixtures and equipment, at cost	2,695,297	3,130,640
Accumulated depreciation	(2,429,580)	(2,923,482)
Equipment, net	265,717	207,158
Right of use asset	1,060,971	1,317,057
Patents, net of accumulated amortization of $317,821 at March 31, 2021 and $291,337 at March 31, 2020	213,368	228,296
Other assets	20,496	19,548
TOTAL ASSETS	5,658,546	4,736,925
Current liabilities:
Accounts payable	389,088	444,823
Line of credit	0	370,498
Secured notes	20,397	0
Accrued compensation	181,686	218,806
Other accrued liabilities	282,102	96,077
Accrued lease liability	302,978	278,271
Total current liabilities	1,176,251	1,408,475
Long-term liability:
Secured notes	220,263	0
Accrued lease liability	926,808	1,144,432
Unsecured promissory note	533,118	0
Total liabilities	2,856,440	2,552,907
Shareholders' equity:
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding	0	0
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 11,582,641 issued and outstanding at March 31, 2021 and 2020	24,265,831	24,232,477
Accumulated (deficit)	(21,463,725)	(22,048,459)
Total shareholders' equity	2,802,106	2,184,018
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 5,658,546	$ 4,736,925

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 35,000	$ 58,000
Inventories, reserve for obsolescence	70,000	39,000
Accumulated amortization	$ 317,821	$ 291,337
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock and additional paid-in capital, shares authorized	100,000,000	100,000,000
Common stock and additional paid-in capital, shares issued	11,582,641	11,582,641
Common stock and additional paid-in capital, shares outstanding	11,582,641	11,582,641

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
NET REVENUE
Total revenue	$ 7,537,834	$ 7,670,206
COST OF REVENUE:
Total cost of revenue	3,632,731	3,666,590
GROSS PROFIT	3,905,103	4,003,616
OPERATING EXPENSES:
Sales and marketing	2,020,435	2,093,564
General and administrative	1,376,767	1,318,022
Research and development	569,542	748,390
Total operating expenses	3,966,744	4,159,976
OPERATING (LOSS)	(61,641)	(156,360)
OTHER INCOME (EXPENSE):
Interest expense, net	(87,127)	(43,382)
Extinguishment of debt income	598,567	0
Other income, net	134,935	1,430
Interest expense, extinguishment of debt income and other income, net	646,375	(41,952)
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES	584,734	(198,312)
Provision for income taxes	0	0
NET INCOME (LOSS)	$ 584,734	$ (198,312)
Net income (loss) per share-basic and diluted	$ 0.05	$ (0.02)
Weighted average shares-basic	11,582,641	11,573,211
Weighted average shares-diluted	11,767,997	11,573,211
Product [Member]
NET REVENUE
Total revenue	$ 7,010,657	$ 7,670,206
COST OF REVENUE:
Total cost of revenue	3,375,307	3,666,590
GROSS PROFIT	3,635,350
OPERATING EXPENSES:
OPERATING (LOSS)	(357,248)
Service [Member]
NET REVENUE
Total revenue	527,177	0
COST OF REVENUE:
Total cost of revenue	257,424	$ 0
GROSS PROFIT	269,753
OPERATING EXPENSES:
OPERATING (LOSS)	$ 269,753

Statements of Shareholders' Equ

Statements of Shareholders' Equity - USD ($)	Common Stock and Additional Paid-in Capital		Accumulated Deficit	Total
Beginning Balance, Shares at Mar. 31, 2019	11,558,355
Beginning Balance, Amount at Mar. 31, 2019	$ 24,201,769		$ (21,850,147)	$ 2,351,622
Net income (loss)			(198,312)	(198,312)
Compensation expense related to equities	$ 30,708			30,708
Common stock issued, Shares	24,286
Common stock issued, Amount		[1]
Ending Balance, Shares at Mar. 31, 2020	11,582,641
Ending Balance, Amount at Mar. 31, 2020	$ 24,232,477		(22,048,459)	2,184,018
Net income (loss)			584,734	584,734
Compensation expense related to equities	$ 33,354			33,354
Ending Balance, Shares at Mar. 31, 2021	11,582,641
Ending Balance, Amount at Mar. 31, 2021	$ 24,265,831		$ (21,463,725)	$ 2,802,106
[1]	Common stock issued was in exchange for restricted stock units that were exercised; no cash was received.

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from (used in) operating activities:
Net income (loss)	$ 584,734	$ (198,312)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Extinguishment of debt income	(598,567)	0
Depreciation and amortization	88,955	137,810
Stock-based compensation expense related to stock options	33,354	30,708
(Recovery from) provision for doubtful accounts, net change	(23,000)	32,000
Provision for (recovery from) for inventory obsolescence, net change	31,000	(11,000)
Other income from release of account payable	(56,435)	0
Change in operating assets and liabilities:
Right of use asset, net	63,169	30,825
Accounts receivable	(120,176)	95,912
Inventories	149,767	(142,358)
Prepaid expenses and other assets	(82,460)	36,490
Accounts payable	700	(134,133)
Accrued compensation and other accrued liabilities	148,905	(107,426)
Net cash provided by (used in) operating activities	219,946	(229,484)
Cash flows (used in) investing activities:
Acquisition of property and equipment	(30,020)	(48,324)
Patent costs	(15,166)	(5,906)
Net cash (used in) investing activities	(45,186)	(54,230)
Cash flows from (used in) financing activities:
(Paydown of) borrowings from credit facility, net change	(370,498)	370,498
Proceeds from secured notes	153,260	0
Proceeds from PPP loans	1,131,685	0
Net cash provided by (used in) financing activities	914,447	370,498
Net increase in cash	1,089,207	86,784
Cash, beginning of fiscal year	385,132	298,348
Cash, end of fiscal year	1,474,339	385,132
Supplemental disclosure of non-cash investing activity information:
Acquisition of property and equipment through secured note payable	87,400	0
Lease asset	0	1,555,150
Lease liability	0	(1,619,842)
Supplemental disclosures of cash flow information:
Cash paid during the year for interest	80,251	43,515
Property and equipment additions transferred from prepaid expenses	$ 0	$ 20,887

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Encision Inc. is a medical device company that designs, develops, manufactures and markets patented surgical instruments that provide greater safety to patients undergoing minimally-invasive surgery. We believe that our patented AEM ® We have an accumulated deficit of $21,463,725 at March 31, 2021. Operating funds have been provided primarily by issuances of our common stock and warrants, the exercise of stock options to purchase our common stock, and by operating profits. Our liquidity has diminished because of prior years’ operating losses, and we may be required to seek additional capital in the future. Our strategic marketing and sales plan is designed to expand the use of our products in surgically active hospitals in the United States. We had net income and a (net loss) available to shareholders of $584,734 and ($198,312) for the fiscal years ended March 31, 2021 and 2020, respectively. At March 31, 2021, we had $1,474,339 in cash available to fund future operations, and outstanding borrowings of $773,778. In February 2021, we entered into an unsecured promissory note under the PPP for a principal amount of $533,118. The PPP was established under the congressionally approved CARES Act. The term of the PPP loan is for two years with an interest rate of 1.0% per year, which will be deferred for the first six months of the term of the loan. After the initial six-month deferral period, the loan requires monthly payments of principal and interest until maturity with respect to any portion of the PPP loan which is not forgiven. Under the terms of the CARES Act, a PPP loan recipient may apply for, and be granted, forgiveness for all or a portion of loans granted under the PPP. Such forgiveness will be determined based upon the use of loan proceeds for payroll costs, rent and utility costs, and the maintenance of employee and compensation levels. We expect to achieve the requirements for forgiveness of the loan. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates in the Preparation of Financial Statements. Cash and Cash Equivalents Fair Value of Financial Instruments. Concentration of Credit Risk. We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with one financial institution in the form of demand deposits. Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We charge interest on past due accounts on a case-by-case basis. A summary of the activity in our allowance for doubtful accounts is as follows: Years Ended March 31, 2021 March 31, 2020 Balance, beginning of year $ 58,000 $ 26,000 Provision for (recoveries of) estimated losses (16,322 ) 32,168 Write-off of uncollectible accounts (6,678 ) (168 ) Balance, end of year $ 35,000 $ 58,000 The net accounts receivable balance at March 31, 2021 of $1,024,370 included no more than 14% from any one customer. The net accounts receivable balance at March 31, 2020 of $881,194 included no more than 8% from any one customer. Warranty Accrual. We provide for the estimated cost of product warranties at the time sales are recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligation is based upon historical experience and is also affected by product failure rates and material usage in correcting a product failure. Should actual product failure rates or material usage costs differ from our estimates, revisions to the estimated warranty liability would be required. There was no warranty accrual at March 31, 2021. Inventories. Inventories are stated at the lower of cost (first-in, first-out basis) or net realizable value. We reduce inventory for estimated obsolete or unmarketable inventory equal to the difference between the cost of inventory and the net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. At March 31, 2021 and 2020, inventory consisted of the following: March 31, 2021 March 31, 2020 Raw materials $ 1,038,094 $ 1,147,983 Finished goods 477,040 516,918 Total gross inventories 1,515,134 1,664,901 Less reserve for obsolescence (70,000 ) (39,000 ) Total net inventories $ 1,445,134 $ 1,625,901 A summary of the activity in our inventory reserve for obsolescence is as follows: Years Ended March 31, 2021 March 31, 2020 Balance, beginning of year $ 39,000 $ 50,000 Provision for estimated obsolescence 31,528 (11,000 ) Write-off of obsolete inventory (528 ) — Balance, end of year $ 70,000 $ 39,000 Property and Equipment. Long-Lived Assets. Patents. March 31, 2021 March 31, 2020 Patents issued $ 496,901 $ 473,607 Accumulated amortization (308,155 ) (281,649 ) Patents issued, net of accumulated amortization 188,746 191,958 Patent applications 34,288 46,026 Accumulated amortization (9,666 ) (9,688 ) Patent applications, net of accumulated amortization 24,622 36,338 Total net patents and patent applications $ 213,368 $ 228,296 The expected annual amortization expense related to patents and patent applications as of March 31, 2021, for the next five fiscal years, is as follows: Fiscal Year Amount 2022 24,705 2023 24,705 2024 21,787 2025 21,037 2026 20,220 Thereafter 100,914 Total $ 213,368 Other Accrued Liabilities. March 31, 2021 March 31, 2020 Bonus $ 95,795 $ 10,000 Sales commissions 45,370 29,994 Sales and use tax 15,065 12,037 Marketing fees 15,330 10,511 Payroll taxes 93,857 22,712 Miscellaneous 16,685 10,823 Total other accrued liabilities $ 282,102 $ 96,077 Income Taxes. ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. The cumulative effect of adopting ASC 740 on April 1, 2007 has been recorded net in deferred tax assets, which resulted in no ASC 740 liability on the balance sheet. The total amount of unrecognized tax benefits as of the date of adoption was zero. There are open statutes of limitations for taxing authorities in federal and state jurisdictions to audit the Company’s tax returns from fiscal year ended March 31, 1999 through the current period. Our policy is to account for income tax related interest and penalties in income tax expense in the statements of operations. There have been no income tax related interest or penalties assessed or recorded. Because the Company has provided a full valuation allowance on all of its deferred tax assets, the adoption of ASC 740 had no impact on our effective tax rate. Revenue Recognition. Sales Taxes. Research and Development Expenses Advertising Costs. Stock-Based Compensation. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the accompanying statements of operations. Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Stock-based compensation expense recognized in our statements of operations for fiscal years 2021 and 2020 included compensation expense for share-based payment awards granted prior to, but not yet vested as of March 31, 2021, based on the grant date fair value. Compensation expense for all share-based payment is recognized using the straight-line, single-option method. As stock-based compensation expense recognized in the accompanying statements of operations for fiscal years 2021 and 2020 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We used the Black-Scholes option-pricing model (“Black-Scholes model”) to determine fair value. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Although the fair value of employee stock options is determined in accordance with ASC 718 using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction. Stock-based compensation expense recognized under ASC 718 for fiscal years 2021 and 2020 was $33,354 and $30,708, respectively, which consisted of stock-based compensation expense related to director and employee stock options. Stock-based compensation expense related to director and employee stock options under ASC 718 for fiscal years 2021 and 2020 was allocated as follows: Years Ended March 31, 2021 March 31, 2020 Cost of sales $ 3,669 $ 2,811 Sales and marketing 4,871 3,317 General and administrative 22,632 22,671 Research and development 2,182 1,909 Stock-based compensation expense $ 33,354 $ 30,708 Segment Reporting. Year Ended March 31, 2021 Product Service Total Net revenue $ 7,010,657 $ 527,177 $ 7,537,834 Cost of revenue 3,375,307 257,424 3,632,731 Gross profit 3,635,350 269,753 3,905,103 Operating income (loss) (357,248 ) 269,753 (61,641 ) Depreciation and amortization 88,955 — 88,955 Capital expenditures 117,420 — 117,420 Equipment and patents, net $ 479,085 $ — $ 479,085 Basic and Diluted Income per Common Share. The following table presents the calculation of basic and diluted net income (loss) per share: Years Ended March 31, 2021 March 31, 2020 Net income (loss) $ 584,734 $ (198,312 ) Weighted-average shares — basic 11,582,641 11,573,211 Effect of dilutive potential common shares 185,356 — Weighted-average shares — basic and diluted 11,767,997 11,573,211 Net loss per share — basic and diluted $ 0.05 $ (0.02 ) Antidilutive equity units 850,644 998,000 Recent Accounting Pronouncements. .

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
Shareholders' Equity	3. Shareholders’ Equity Stock Option Plans. Under ASC 718, the value of each employee stock option was estimated on the date of grant using the Black-Scholes model for the purpose of financial information in accordance with ASC 718. The use of a Black-Scholes model requires the use of actual employee exercise behavior data and the use of a number of assumptions including expected volatility, risk-free interest rate and expected dividends. Employee stock options for 110,000 and 185,000 shares of stock were granted during fiscal years 2021 and 2020, respectively. As of March 31, 2021, $73,000 of total unrecognized compensation costs related to nonvested stock is expected to be recognized over a period of five years. The assumptions for employee stock options are summarized as follows: Years Ended March 31, 2021 March 31, 2020 Risk-free interest rate 0.3% to 0.4% 1.2% to 2.4% Expected life (in years) 5.0 5.0 Expected volatility 87% 87% to 89% Expected dividend 0% 0% Cumulative compensation cost recognized in net income or loss with respect to options that are forfeited prior to vesting is adjusted as a reduction of compensation expense in the period of forfeiture. The volatility of the stock is based on the historical volatility for the period that approximates the expected lives of the options being valued. Fair value computations are highly sensitive to the volatility factor; the greater the volatility, the higher the computed fair value of options granted. The total fair value of options granted was computed to be approximately $40,000 and $62,000, for the fiscal years ended March 31, 2021 and 2020, respectively. For disclosure purposes, these amounts are amortized ratably over the vesting periods of the options. Effects of stock-based compensation, net of the effect of forfeitures, totaled $33,354 and $30,708 for fiscal years 2021 and 2020, respectively. The Black-Scholes model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the use of assumptions, including the expected stock price volatility. Because our employee stock options have characteristics significantly different than those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of our employee stock options. A summary of our stock option activity and related information for equity compensation plans approved by security holders for each of the fiscal years ended March 31, 2021 and 2020 is as follows: STOCK OPTIONS OUTSTANDING Number Outstanding Weighted-Average Exercise Price per Share BALANCE AT MARCH 31, 2019 672,000 $ 0.43 Granted 185,000 0.42 Forfeited/expired (103,000 ) 0.71 BALANCE AT MARCH 31, 2020 754,000 $ 0.39 Granted 110,000 0.54 Forfeited/expired (72,000 ) 0.51 BALANCE AT MARCH 31, 2021 792,000 $ 0.40 A summary of our stock option activity and related information for equity compensation plans not approved by security holders for the fiscal year ended March 31, 2021 is as follows: STOCK OPTIONS OUTSTANDING Number Outstanding Weighted-Average Exercise Price per Share BALANCE AT MARCH 31, 2019 294,000 $ 0.49 Forfeited/expired (50,000 ) 0.36 BALANCE AT MARCH 31, 2020 244,000 $ 0.52 Forfeited/expired 0 0.00 BALANCE AT MARCH 31, 2021 244,000 $ 0.52 The following table summarizes information about employee stock options outstanding and exercisable at March 31, 2021: STOCK OPTIONS OUTSTANDING STOCK OPTIONS EXERCISABLE Range of Exercise Prices Number Outstanding Weighted-Average Remaining Contractual Life (in Years) Weighted-Average Exercise Price per Share Number Exercisable Weighted-Average Exercise Price per Share $0.30 - $0.35 550,000 2.3 $ 0.33 341,878 $ 0.32 $0.38 - $0.50 431,000 2.2 $ 0.43 226,056 $ 0.42 $0.54 - $0.67 55,000 4.9 $ 0.59 7,700 $ 0.55 1,036,000 2.4 $ 0.39 575,634 $ 0.36 The 1,036,000 options outstanding as of March 31, 2021 are nonqualified stock options. The exercise price of all options granted through March 31, 2021 has been equal to or greater than the fair market value, as determined by our Board of Directors or based upon publicly quoted market values of our common stock on the date of the grant.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	4. Commitments and Contingencies We have a noncancelable lease agreement for our facilities at 6797 Winchester Circle, Boulder, Colorado. The lease expires October 31, 2024. On April 1, 2020, we adopted Accounting Standards Codification (“ASC”) ASC 842 “Leases” using the initial date of adoption method, whereby the adoption does not impact any periods prior to April 1, 2019. ASC Topic 842 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases’ guidance. We recorded an operating Right of Use (“ROU”) asset of $1,555,150, and an operating lease liability of $1,619,842 as of April 1, 2019. The difference between the initial operating ROU asset and operating lease liability of $64,692 is accrued rent previously recorded under ASC 840. We elected to adopt the package of practical expedients and, accordingly, did not reassess any previously expired or existing arrangements and related classifications under ASC 840. If the rate implicit in the lease is not readily determinable, we use our incremental borrowing rate as the discount rate. We use our best judgement when determining the incremental borrowing rate, which is the rate of interest that we would have to pay to borrow on a collateralized basis over a similar term to the lease payments. Our operating lease includes the use of real property. We have not identified any material finance leases as of March 31, 2021. For the years ended March 31, 2021 and 2020, we had $322,961 and $297,648, respectively, for lease expense. The following is a maturity analysis of the annual undiscounted cash flows reconciled to the carrying value of the operating lease liabilities as of March 31, 2021: Fiscal Year Amount 2022 357,667 2023 372,167 2024 386,667 2025 232,139 Total operating lease payments 1,348,640 Less imputed interest (118,854 ) Total operating lease liabilities $ 1,229,786 Weighted-average remaining lease term 3.5 years Weighted-average discount rate 5.0 % During January 2021, we canceled our relationship with Crestmark Bank. We had no borrowings and incurred a $20,000 exit fee. Under our agreement with Crestmark Bank, we were provided with a line of credit that was not to exceed the lesser of $1,000,000 or 85% of eligible accounts receivable. The interest rate was prime rate plus 1.5%, with a floor of 6.75%, plus a monthly maintenance fee of 0.4%, based on the average monthly loan balance. Interest was charged on a minimum loan balance of $500,000, a loan fee of 1% annually, and an exit fee of 3%, 2% and 1% during years one, two and three, respectively. On August 4, 2020, we received $150,000 in loan funding from the U.S. Small Business Administration (“SBA”) under the Economic Injury Disaster Loan (“EIDL”) program administered by the SBA, which program was expanded pursuant to the CARES Act. The EIDL is evidenced by a promissory note, dated August 1, 2020 in the original principal amount of $150,000 with the SBA, the lender. Under the terms of the Note, interest accrues on the outstanding principal at the rate of 3.75% per annum. The term of the Note is thirty years, though it may be payable sooner upon an event of default under the Note. Under the Note, we will be obligated to make equal monthly payments of principal and interest of $731 beginning on August 1, 2021 through the maturity date of August 1, 2050. The Note may be prepaid in part or in full, at any time, without penalty. During January 2021, we entered into a note agreement with U.S. Bank for $92,000. The note is for five years at a 5% interest rate and the proceeds were used to purchase equipment. The note is secured by the equipment. On February 8, 2021, we entered into an unsecured promissory note under the PPP for a principal amount of $533,118. The PPP was established under the Consolidated Appropriations Act of 2020, enacted December 27, 2020. Under the terms of the CARES Act, a PPP loan recipient may apply for, and be granted, forgiveness for all or a portion of loans granted under the PPP. Such forgiveness will be determined based upon the use of loan proceeds for payroll costs, rent and utility costs, and the maintenance of employee and compensation levels. This was our second PPP loan. On April 17, 2020, we entered into an unsecured promissory note under the PPP for a principal amount of $598,567. In the quarter that ended December 31, 2020, we achieved the requirements for forgiveness, and all of the $598,567 was forgiven. We recognized the forgiveness as extinguishment of debt income of $598,567. We expect that we will achieve the requirements for forgiveness of the February 8, 2021 PPP note. The minimum future EIDL payment, by fiscal year, as of March 31, 2021 is as follows: Fiscal Year Amount 2022 1,997 2023 3,091 2024 3,208 2025 3,331 2026 3,457 Thereafter 136,916 Total $ 152,000 The minimum future U.S. Bank payment, by fiscal year, as of March 31, 2021 is as follows: Fiscal Year Amount 2022 18,400 2023 18,400 2024 18,400 2025 18,400 2026 15,060 Total $ 88,660 We are subject to regulation by the United States Food and Drug Administration (“FDA”). The FDA provides regulations governing the manufacture and sale of our products and regularly inspects us and other manufacturers to determine our and their compliance with these regulations. As of March 31, 2021, we believe we were in substantial compliance with all known regulations. FDA inspections are conducted periodically at the discretion of the FDA. We were last inspected in October 2019. Our obligation with respect to employee severance benefits is minimized by the “at will” nature of the employee relationships. Our total obligation with respect to contingent severance benefit obligations was none as of March 31, 2021 and 2020.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	5. Income Taxes We account for income taxes under ASC 740, which requires the use of the liability method. ASC 740 provides that deferred income tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. Deferred income tax assets and liabilities at the end of each period are determined using the currently enacted tax rates applied to taxable income in the periods in which the deferred income tax assets and liabilities are expected to be settled or realized. Income tax provision (benefit) for income taxes is summarized below: Years Ended March 31, 2021 March 31, 2020 Current: Federal $ –– $ –– State –– –– Total current — — Deferred: Federal 228,000 442,000 State 44,000 71,000 Total deferred 272,000 513,000 Valuation allowance (272,000 ) (513,000 ) Total $ — $ — The following is a reconciliation between the effective rate and the federal statutory rate: Years Ended March 31, 2021 March 31, 2020 Expected income tax rate $ 123,000 $ (42,000 ) State income taxes, net of federal tax benefit 23,000 (9,000 ) PPP forgiveness (150,000 ) Other permanent differences 1,000 10,000 Research credits (40,000 ) (35,000 ) Change in valuation allowance 43,000 76,000 Income tax expense $ — $ — The components of the net accumulated deferred income tax asset (liability) are as follows: Years Ended March 31, 2021 March 31, 2020 Other deferred assets $ 148,000 $ 71,000 Valuation allowance (148,000 ) (71,000 ) Current deferred tax assets — — Credits and net operating loss carryforwards 2,151,000 2,222,000 Valuation allowance (2,151,000 ) (2,222,000 ) Long-term deferred tax assets — — Total deferred tax assets — — Valuation allowance — — Long-term deferred tax liabilities — — Total deferred tax liabilities — — Net deferred tax assets (liabilities) $ — $ — The primary components of our deferred tax assets are described below: Years Ended March 31, 2021 March 31, 2020 Differences in reporting long-term assets $ 148,000 $ 71,000 Credits and net operating loss carryforwards 2,151,000 2,222,000 Less valuation allowance (2,299,000 ) (2,293,000 ) Total deferred tax assets $ — $ — In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which net operating losses and reversal of timing differences may offset taxable income. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to our lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. As of March 31, 2021, we had approximately $7.1 million of net operating loss carryovers for tax purposes. Additionally, we have approximately $367,000 of research and development tax credits available to offset future federal income taxes. The net operating loss and credit carryovers begin to expire in the fiscal year ended March 31, 2022. In fiscal years ended after March 31, 2022, net operating losses expire at various dates through March 31, 2041. Our net operating loss carryovers at March 31, 2021 include $455,000 in income tax deductions related to stock options which will be tax effected and the benefit will be reflected as a credit to additional paid-in capital when realized. As such, these deductions are not reflected in our deferred tax assets. The Internal Revenue Code contains provisions, which may limit the net operating loss carryforwards available to be used in any given year if certain events occur, including significant changes in ownership interests.

Major Customers_Suppliers

Major Customers/Suppliers	12 Months Ended
	Mar. 31, 2021
Major Customers/Suppliers
Major Customers/Suppliers	6. Major Customers/Suppliers We depend on sales that are generated from hospitals’ ongoing usage of AEM surgical instruments. In fiscal year 2021, we generated sales from over 300 hospitals that have changed to AEM products. Auris Health contributed 10% to the total sales. Three vendors accounted for approximately 47% of our inventory purchases.

Defined Contribution Employee B

Defined Contribution Employee Benefit Plan	12 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Defined Contribution Employee Benefit Plan	7. Defined Contribution Employee Benefit Plan We have adopted a 401(k) Profit Sharing Plan which covers all full-time employees who have completed at least three months of full-time continuous service and are age eighteen or older. Participants may defer up to 20% of their gross pay up to a maximum limit determined by law. Participants are immediately vested in their contributions. We may make discretionary contributions based on corporate financial results for the fiscal year. To date, we have not made contributions to the 401(k) Profit Sharing Plan. Vesting in a contribution account (our contribution) is based on years of service, with a participant fully vested after five years of credited service.

Related Party Transaction

Related Party Transaction	12 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transaction	8. Related Party Transaction We paid consulting fees of $66,003 and $69,189 to an entity owned by one of our directors in fiscal years 2021 and 2020, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events Management evaluated all of our activity and concluded that, as of the date the financial statements were issued, no subsequent events have occurred that would require recognition in the financial statements or disclosure in the notes to the financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements.
Cash, Cash Equivalents and Restricted Cash	Cash and Cash Equivalents
Fair Value of Financial Instruments	Fair Value of Financial Instruments.
Concentration of Credit Risk	Concentration of Credit Risk. We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with one financial institution in the form of demand deposits. Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We charge interest on past due accounts on a case-by-case basis. A summary of the activity in our allowance for doubtful accounts is as follows: Years Ended March 31, 2021 March 31, 2020 Balance, beginning of year $ 58,000 $ 26,000 Provision for (recoveries of) estimated losses (16,322 ) 32,168 Write-off of uncollectible accounts (6,678 ) (168 ) Balance, end of year $ 35,000 $ 58,000 The net accounts receivable balance at March 31, 2021 of $1,024,370 included no more than 14% from any one customer. The net accounts receivable balance at March 31, 2020 of $881,194 included no more than 8% from any one customer.
Warranty Accrual	Warranty Accrual. We provide for the estimated cost of product warranties at the time sales are recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligation is based upon historical experience and is also affected by product failure rates and material usage in correcting a product failure. Should actual product failure rates or material usage costs differ from our estimates, revisions to the estimated warranty liability would be required. There was no warranty accrual at March 31, 2021.
Inventories	Inventories. Inventories are stated at the lower of cost (first-in, first-out basis) or net realizable value. We reduce inventory for estimated obsolete or unmarketable inventory equal to the difference between the cost of inventory and the net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. At March 31, 2021 and 2020, inventory consisted of the following: March 31, 2021 March 31, 2020 Raw materials $ 1,038,094 $ 1,147,983 Finished goods 477,040 516,918 Total gross inventories 1,515,134 1,664,901 Less reserve for obsolescence (70,000 ) (39,000 ) Total net inventories $ 1,445,134 $ 1,625,901 A summary of the activity in our inventory reserve for obsolescence is as follows: Years Ended March 31, 2021 March 31, 2020 Balance, beginning of year $ 39,000 $ 50,000 Provision for estimated obsolescence 31,528 (11,000 ) Write-off of obsolete inventory (528 ) — Balance, end of year $ 70,000 $ 39,000
Property and Equipment	Property and Equipment.
Long-Lived Assets	Long-Lived Assets.
Patents	Patents. March 31, 2021 March 31, 2020 Patents issued $ 496,901 $ 473,607 Accumulated amortization (308,155 ) (281,649 ) Patents issued, net of accumulated amortization 188,746 191,958 Patent applications 34,288 46,026 Accumulated amortization (9,666 ) (9,688 ) Patent applications, net of accumulated amortization 24,622 36,338 Total net patents and patent applications $ 213,368 $ 228,296 The expected annual amortization expense related to patents and patent applications as of March 31, 2021, for the next five fiscal years, is as follows: Fiscal Year Amount 2022 24,705 2023 24,705 2024 21,787 2025 21,037 2026 20,220 Thereafter 100,914 Total $ 213,368
Other Accrued Liabilities	Other Accrued Liabilities. March 31, 2021 March 31, 2020 Bonus $ 95,795 $ 10,000 Sales commissions 45,370 29,994 Sales and use tax 15,065 12,037 Marketing fees 15,330 10,511 Payroll taxes 93,857 22,712 Miscellaneous 16,685 10,823 Total other accrued liabilities $ 282,102 $ 96,077
Income Taxes	Income Taxes. ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. The cumulative effect of adopting ASC 740 on April 1, 2007 has been recorded net in deferred tax assets, which resulted in no ASC 740 liability on the balance sheet. The total amount of unrecognized tax benefits as of the date of adoption was zero. There are open statutes of limitations for taxing authorities in federal and state jurisdictions to audit the Company’s tax returns from fiscal year ended March 31, 1999 through the current period. Our policy is to account for income tax related interest and penalties in income tax expense in the statements of operations. There have been no income tax related interest or penalties assessed or recorded. Because the Company has provided a full valuation allowance on all of its deferred tax assets, the adoption of ASC 740 had no impact on our effective tax rate.
Revenue Recognition	Revenue Recognition.
Sales Taxes	Sales Taxes.
Research and Development Expenses	Research and Development Expenses
Advertising Costs	Advertising Costs.
Stock-Based Compensation	Stock-Based Compensation. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the accompanying statements of operations. Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Stock-based compensation expense recognized in our statements of operations for fiscal years 2021 and 2020 included compensation expense for share-based payment awards granted prior to, but not yet vested as of March 31, 2021, based on the grant date fair value. Compensation expense for all share-based payment is recognized using the straight-line, single-option method. As stock-based compensation expense recognized in the accompanying statements of operations for fiscal years 2021 and 2020 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We used the Black-Scholes option-pricing model (“Black-Scholes model”) to determine fair value. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Although the fair value of employee stock options is determined in accordance with ASC 718 using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction. Stock-based compensation expense recognized under ASC 718 for fiscal years 2021 and 2020 was $33,354 and $30,708, respectively, which consisted of stock-based compensation expense related to director and employee stock options. Stock-based compensation expense related to director and employee stock options under ASC 718 for fiscal years 2021 and 2020 was allocated as follows: Years Ended March 31, 2021 March 31, 2020 Cost of sales $ 3,669 $ 2,811 Sales and marketing 4,871 3,317 General and administrative 22,632 22,671 Research and development 2,182 1,909 Stock-based compensation expense $ 33,354 $ 30,708
Segment Reporting	Segment Reporting. Year Ended March 31, 2021 Product Service Total Net revenue $ 7,010,657 $ 527,177 $ 7,537,834 Cost of revenue 3,375,307 257,424 3,632,731 Gross profit 3,635,350 269,753 3,905,103 Operating income (loss) (357,248 ) 269,753 (61,641 ) Depreciation and amortization 88,955 — 88,955 Capital expenditures 117,420 — 117,420 Equipment and patents, net $ 479,085 $ — $ 479,085
Basic and Diluted Income per Common Share	Basic and Diluted Income per Common Share. The following table presents the calculation of basic and diluted net income (loss) per share: Years Ended March 31, 2021 March 31, 2020 Net income (loss) $ 584,734 $ (198,312 ) Weighted-average shares — basic 11,582,641 11,573,211 Effect of dilutive potential common shares 185,356 — Weighted-average shares — basic and diluted 11,767,997 11,573,211 Net loss per share — basic and diluted $ 0.05 $ (0.02 ) Antidilutive equity units 850,644 998,000
Recent Accounting Pronouncements	Recent Accounting Pronouncements. .

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of the activity in allowance for doubtful accounts	A summary of the activity in our allowance for doubtful accounts is as follows: Years Ended March 31, 2021 March 31, 2020 Balance, beginning of year $ 58,000 $ 26,000 Provision for (recoveries of) estimated losses (16,322 ) 32,168 Write-off of uncollectible accounts (6,678 ) (168 ) Balance, end of year $ 35,000 $ 58,000
Schedule of inventory	At March 31, 2021 and 2020, inventory consisted of the following: March 31, 2021 March 31, 2020 Raw materials $ 1,038,094 $ 1,147,983 Finished goods 477,040 516,918 Total gross inventories 1,515,134 1,664,901 Less reserve for obsolescence (70,000 ) (39,000 ) Total net inventories $ 1,445,134 $ 1,625,901
Summary of the activity in inventory reserve for obsolescence	A summary of the activity in our inventory reserve for obsolescence is as follows: Years Ended March 31, 2021 March 31, 2020 Balance, beginning of year $ 39,000 $ 50,000 Provision for estimated obsolescence 31,528 (11,000 ) Write-off of obsolete inventory (528 ) — Balance, end of year $ 70,000 $ 39,000
Summary of patents	A summary of our patents at March 31, 2021 and 2020 is as follows: March 31, 2021 March 31, 2020 Patents issued $ 496,901 $ 473,607 Accumulated amortization (308,155 ) (281,649 ) Patents issued, net of accumulated amortization 188,746 191,958 Patent applications 34,288 46,026 Accumulated amortization (9,666 ) (9,688 ) Patent applications, net of accumulated amortization 24,622 36,338 Total net patents and patent applications $ 213,368 $ 228,296
Schedule of expected annual amortization expense related to patents and patent applications for the next five fiscal years	The expected annual amortization expense related to patents and patent applications as of March 31, 2021, for the next five fiscal years, is as follows: Fiscal Year Amount 2022 24,705 2023 24,705 2024 21,787 2025 21,037 2026 20,220 Thereafter 100,914 Total $ 213,368
Schedule of other accrued liabilities	Other Accrued Liabilities. March 31, 2021 March 31, 2020 Bonus $ 95,795 $ 10,000 Sales commissions 45,370 29,994 Sales and use tax 15,065 12,037 Marketing fees 15,330 10,511 Payroll taxes 93,857 22,712 Miscellaneous 16,685 10,823 Total other accrued liabilities $ 282,102 $ 96,077
Schedule of stock-based compensation expense related to employee stock options	Stock-based compensation expense related to director and employee stock options under ASC 718 for fiscal years 2021 and 2020 was allocated as follows: Years Ended March 31, 2021 March 31, 2020 Cost of sales $ 3,669 $ 2,811 Sales and marketing 4,871 3,317 General and administrative 22,632 22,671 Research and development 2,182 1,909 Stock-based compensation expense $ 33,354 $ 30,708
Schedule of service performs electrical engineering activities for external entities	Service performs electrical engineering activities for external entities. Year Ended March 31, 2021 Product Service Total Net revenue $ 7,010,657 $ 527,177 $ 7,537,834 Cost of revenue 3,375,307 257,424 3,632,731 Gross profit 3,635,350 269,753 3,905,103 Operating income (loss) (357,248 ) 269,753 (61,641 ) Depreciation and amortization 88,955 — 88,955 Capital expenditures 117,420 — 117,420 Equipment and patents, net $ 479,085 $ — $ 479,085
Schedule of calculation of basic and diluted net income (loss) per share	The following table presents the calculation of basic and diluted net income (loss) per share: Years Ended March 31, 2021 March 31, 2020 Net income (loss) $ 584,734 $ (198,312 ) Weighted-average shares — basic 11,582,641 11,573,211 Effect of dilutive potential common shares 185,356 — Weighted-average shares — basic and diluted 11,767,997 11,573,211 Net loss per share — basic and diluted $ 0.05 $ (0.02 ) Antidilutive equity units 850,644 998,000

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
Summary of assumptions for employee stock options	As of March 31, 2021, $73,000 of total unrecognized compensation costs related to nonvested stock is expected to be recognized over a period of five years. The assumptions for employee stock options are summarized as follows: Years Ended March 31, 2021 March 31, 2020 Risk-free interest rate 0.3% to 0.4% 1.2% to 2.4% Expected life (in years) 5.0 5.0 Expected volatility 87% 87% to 89% Expected dividend 0% 0%
Summary of stock option activity and related information for equity compensation plans	A summary of our stock option activity and related information for equity compensation plans approved by security holders for each of the fiscal years ended March 31, 2021 and 2020 is as follows: STOCK OPTIONS OUTSTANDING Number Outstanding Weighted-Average Exercise Price per Share BALANCE AT MARCH 31, 2019 672,000 $ 0.43 Granted 185,000 0.42 Forfeited/expired (103,000 ) 0.71 BALANCE AT MARCH 31, 2020 754,000 $ 0.39 Granted 110,000 0.54 Forfeited/expired (72,000 ) 0.51 BALANCE AT MARCH 31, 2021 792,000 $ 0.40
Summary of RSU activity and related information for equity compensation plans	A summary of our stock option activity and related information for equity compensation plans not approved by security holders for the fiscal year ended March 31, 2021 is as follows: STOCK OPTIONS OUTSTANDING Number Outstanding Weighted-Average Exercise Price per Share BALANCE AT MARCH 31, 2019 294,000 $ 0.49 Forfeited/expired (50,000 ) 0.36 BALANCE AT MARCH 31, 2020 244,000 $ 0.52 Forfeited/expired 0 0.00 BALANCE AT MARCH 31, 2021 244,000 $ 0.52
Summary of information about employee stock options outstanding and exercisable	The following table summarizes information about employee stock options outstanding and exercisable at March 31, 2021: STOCK OPTIONS OUTSTANDING STOCK OPTIONS EXERCISABLE Range of Exercise Prices Number Outstanding Weighted-Average Remaining Contractual Life (in Years) Weighted-Average Exercise Price per Share Number Exercisable Weighted-Average Exercise Price per Share $0.30 - $0.35 550,000 2.3 $ 0.33 341,878 $ 0.32 $0.38 - $0.50 431,000 2.2 $ 0.43 226,056 $ 0.42 $0.54 - $0.67 55,000 4.9 $ 0.59 7,700 $ 0.55 1,036,000 2.4 $ 0.39 575,634 $ 0.36

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Mar. 31, 2021
Schedule of minimum future lease payments, by fiscal year	The following is a maturity analysis of the annual undiscounted cash flows reconciled to the carrying value of the operating lease liabilities as of March 31, 2021: Fiscal Year Amount 2022 357,667 2023 372,167 2024 386,667 2025 232,139 Total operating lease payments 1,348,640 Less imputed interest (118,854 ) Total operating lease liabilities $ 1,229,786 Weighted-average remaining lease term 3.5 years Weighted-average discount rate 5.0 %
EIDL payment [Member]
Schedule of minimum future lease payments, by fiscal year	The minimum future EIDL payment, by fiscal year, as of March 31, 2021 is as follows: Fiscal Year Amount 2022 1,997 2023 3,091 2024 3,208 2025 3,331 2026 3,457 Thereafter 136,916 Total $ 152,000
U.S. Bank payment [Member]
Schedule of minimum future lease payments, by fiscal year	The minimum future U.S. Bank payment, by fiscal year, as of March 31, 2021 is as follows: Fiscal Year Amount 2022 18,400 2023 18,400 2024 18,400 2025 18,400 2026 15,060 Total $ 88,660

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of components of income tax expense (benefit)	Income tax provision (benefit) for income taxes is summarized below: Years Ended March 31, 2021 March 31, 2020 Current: Federal $ –– $ –– State –– –– Total current — — Deferred: Federal 228,000 442,000 State 44,000 71,000 Total deferred 272,000 513,000 Valuation allowance (272,000 ) (513,000 ) Total $ — $ —
Schedule of Effective Income Tax Rate Reconciliation	The following is a reconciliation between the effective rate and the federal statutory rate: Years Ended March 31, 2021 March 31, 2020 Expected income tax rate $ 123,000 $ (42,000 ) State income taxes, net of federal tax benefit 23,000 (9,000 ) PPP forgiveness (150,000 ) Other permanent differences 1,000 10,000 Research credits (40,000 ) (35,000 ) Change in valuation allowance 43,000 76,000 Income tax expense $ — $ —
Schedule of components of the deferred tax asset	The components of the net accumulated deferred income tax asset (liability) are as follows: Years Ended March 31, 2021 March 31, 2020 Other deferred assets $ 148,000 $ 71,000 Valuation allowance (148,000 ) (71,000 ) Current deferred tax assets — — Credits and net operating loss carryforwards 2,151,000 2,222,000 Valuation allowance (2,151,000 ) (2,222,000 ) Long-term deferred tax assets — — Total deferred tax assets — — Valuation allowance — — Long-term deferred tax liabilities — — Total deferred tax liabilities — — Net deferred tax assets (liabilities) $ — $ — The primary components of our deferred tax assets are described below: Years Ended March 31, 2021 March 31, 2020 Differences in reporting long-term assets $ 148,000 $ 71,000 Credits and net operating loss carryforwards 2,151,000 2,222,000 Less valuation allowance (2,299,000 ) (2,293,000 ) Total deferred tax assets $ — $ —

Description of Business and B_2

Description of Business and Basis of Presentation (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 28, 2021	Mar. 31, 2021	Mar. 31, 2020	Feb. 08, 2021	Apr. 17, 2020
Accumulated deficit		$ 21,463,725	$ 22,048,459
Net (loss) income available to shareholders		584,734	$ (198,312)
Cash available to fund future operations		1,474,339
Borrowed		$ 773,778
PPP Loan
Principal amount	$ 533,118			$ 533,118	$ 598,567
Term	2 years
Interest rate	1.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Abstract]
Balance, beginning of year	$ 58,000	$ 26,000
Provision for (recoveries of) estimated losses	(16,322)	32,168
Write-off of uncollectible accounts	(6,678)	(168)
Balance, end of year	$ 35,000	$ 58,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Abstract]
Raw materials	$ 1,038,094	$ 1,147,983
Finished goods	477,040	516,918
Total gross inventories	1,515,134	1,664,901
Less reserve for obsolescence	(70,000)	(39,000)
Total net inventories	$ 1,445,134	$ 1,625,901

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 2) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Abstract]
Balance, beginning of year	$ 39,000	$ 50,000
Provision for estimated obsolescence	31,528	(11,000)
Write-off of obsolete inventory	(528)	0
Balance, end of year	$ 70,000	$ 39,000

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details 3) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Accumulated amortization	$ (317,821)	$ (291,337)
Total net patents and patent applications	213,368	228,296
Patents [Member]
Patents issued	496,901	473,607
Accumulated amortization	(308,155)	(281,649)
Patents issued, net of accumulated amortization	188,746	191,958
Patent applications	34,288	46,026
Accumulated amortization	(9,666)	(9,688)
Patent applications, net of accumulated amortization	24,622	36,338
Total net patents and patent applications	$ 213,368	$ 228,296

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details 4) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Expected annual amortization expense related to patents and patent applications
2022	$ 24,705
2023	24,705
2024	21,787
2025	21,037
2026	20,220
2025 and following	100,914
Total	$ 213,368	$ 228,296

Summary of Significant Accoun_9

Summary of Significant Accounting Policies (Details 5) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Abstract]
Bonus	$ 95,795	$ 10,000
Sales commissions	45,370	29,994
Sales and use tax	15,065	12,037
Marketing fees	15,330	10,511
Payroll taxes	93,857	22,712
Miscellaneous	16,685	10,823
Total other accrued liabilities	$ 282,102	$ 96,077

Summary of Significant Accou_10

Summary of Significant Accounting Policies (Details 6) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock-based compensation expense related to grants of employee stock options	$ 33,354	$ 30,708
Cost Of Sales [Member]
Stock-based compensation expense related to grants of employee stock options	3,669	2,811
Selling And Marketing Expense [Member]
Stock-based compensation expense related to grants of employee stock options	4,871	3,317
General And Administrative Expense [Member]
Stock-based compensation expense related to grants of employee stock options	22,632	22,671
Research And Development Expense [Member]
Stock-based compensation expense related to grants of employee stock options	$ 2,182	$ 1,909

Summary of Significant Accou_11

Summary of Significant Accounting Policies (Details 7) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net revenue	$ 7,537,834	$ 7,670,206
Cost of revenue	3,632,731	3,666,590
Gross profit	3,905,103	4,003,616
Operating income (loss)	(61,641)	(156,360)
Depreciation and amortization	88,955
Capital expenditures	117,420
Equipment and patents, net	479,085
Product [Member]
Net revenue	7,010,657	7,670,206
Cost of revenue	3,375,307	3,666,590
Gross profit	3,635,350
Operating income (loss)	(357,248)
Depreciation and amortization	88,955
Capital expenditures	117,420
Equipment and patents, net	479,085
Service [Member]
Net revenue	527,177	0
Cost of revenue	257,424	$ 0
Gross profit	269,753
Operating income (loss)	269,753
Depreciation and amortization	0
Capital expenditures	0
Equipment and patents, net	$ 0

Summary of Significant Accou_12

Summary of Significant Accounting Policies (Details 8) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Abstract]
Net income (loss)	$ 584,734	$ (198,312)
Weighted-average shares - basic	11,582,641	11,573,211
Effect of dilutive potential common shares	185,356	0
Weighted-average shares - basic and diluted	11,767,997	11,573,211
Net loss per share-basic and diluted	$ 0.05	$ (0.02)
Antidilutive equity units	850,644	998,000

Summary of Significant Accou_13

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Abstract]
Accounts receivable	$ 1,024,370	$ 881,194
Depreciation expense	58,861	111,721
Stock based compensation	$ 33,354	$ 30,708

Shareholders' Equity (Details)

Shareholders' Equity (Details)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Equity [Abstract]
Risk-free interest rate, minimum	0.30%	1.20%
Risk-free interest rate, maximum	0.40%	2.40%
Expected life	5 years	5 years
Expected volatility, minimum	87.00%	87.00%
Expected volatility, maximum		89.00%
Expected dividend	0.00%	0.00%

Shareholders' Equity (Details 1

Shareholders' Equity (Details 1) - Employee Stock Option [Member] - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Equity Compensation Plans Approved [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance at the beginning of the period	754,000	672,000
Granted	110,000	185,000
Forfeited/expired	(72,000)	(103,000)
Balance at the end of the period	792,000	754,000
Balance at the beginning of the period	$ 0.39	$ 0.43
Granted	0.54	0.42
Forfeited/expired	0.51	0.71
Balance at the end of the period	$ 0.40	$ 0.39
Equity Compensation Plans Not Approved [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance at the beginning of the period	244,000	294,000
Forfeited/expired	0	(50,000)
Balance at the end of the period	244,000	244,000
Balance at the beginning of the period	$ 0.52	$ 0.49
Forfeited/expired	0	0.36
Balance at the end of the period	$ 0.52	$ 0.52

Shareholders' Equity (Details 2

Shareholders' Equity (Details 2) - Employee Stock Option [Member]	12 Months Ended
	Mar. 31, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding | shares	1,036,000
Weighted-Average Remaining Contractual Life	2 years 4 months 24 days
Weighted-Average Exercise Price per Share | $ / shares	$ 0.39
Number Exercisable | shares	575,634
Exercisable Weighted-Average Exercise Price per Share | $ / shares	$ 0.36
$0.30 - $0.35 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding | shares	550,000
Weighted-Average Remaining Contractual Life	2 years 3 months 19 days
Weighted-Average Exercise Price per Share | $ / shares	$ 0.33
Number Exercisable | shares	341,878
Exercisable Weighted-Average Exercise Price per Share | $ / shares	$ 0.32
$0.38 - $0.50 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding | shares	431,000
Weighted-Average Remaining Contractual Life	2 years 2 months 12 days
Weighted-Average Exercise Price per Share | $ / shares	$ 0.43
Number Exercisable | shares	226,056
Exercisable Weighted-Average Exercise Price per Share | $ / shares	$ 0.42
$0.54 - $0.67 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding | shares	55,000
Weighted-Average Remaining Contractual Life	4 years 10 months 25 days
Weighted-Average Exercise Price per Share | $ / shares	$ 0.59
Number Exercisable | shares	7,700
Exercisable Weighted-Average Exercise Price per Share | $ / shares	$ 0.55

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Employee stock options granted	110,000	185,000
Unrecognized compensation costs	$ 73,000
Fair value of stock options	40,000	$ 62,000
Stock-based compensation, net of the effect of forfeitures	$ 33,354	$ 30,708
Employee Stock Option [Member]
Nonqualified stock options outstanding	1,036,000

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	Mar. 31, 2021	Apr. 02, 2019
Minimum future lease payments, by fiscal year
2022	$ 357,667
2023	372,167
2024	386,667
2025	232,139
Total operating lease payments	1,348,640
Less imputed interest	(118,854)
Total operating lease liabilities	$ 1,229,786	$ 1,619,842
Weighted-average remaining lease term	3 years 6 months
Weighted-average discount rate	5.00%
EIDL payment [Member]
Minimum future lease payments, by fiscal year
2022	$ 1,997
2023	3,091
2024	3,208
2025	3,331
2026	3,457
Thereafter	136,916
Total operating lease payments	152,000
U.S. Bank payment [Member]
Minimum future lease payments, by fiscal year
2022	18,400
2023	18,400
2024	18,400
2025	18,400
2026	15,060
Total operating lease payments	$ 88,660

Commitments and Contingencies_3

Commitments and Contingencies (Details Narrative) - USD ($)	Feb. 08, 2021	Aug. 01, 2020	Apr. 02, 2019	Feb. 28, 2021	Mar. 31, 2021	Mar. 31, 2020	Apr. 17, 2020
Operating Right of Use asset			$ 1,555,150		$ 1,060,971	$ 1,317,057
Operating lease liability			1,619,842		$ 1,229,786
Difference between initial operating ROU asset and operating lease liability			$ 64,692
Loan description					We had no borrowings and incurred a $20,000 exit fee. Under our agreement with Crestmark Bank, we were provided with a line of credit that was not to exceed the lesser of $1,000,000 or 85% of eligible accounts receivable. The interest rate was prime rate plus 1.5%, with a floor of 6.75%, plus a monthly maintenance fee of 0.4%, based on the average monthly loan balance. Interest was charged on a minimum loan balance of $500,000, a loan fee of 1% annually, and an exit fee of 3%, 2% and 1% during years one, two and three, respectively.
Additional current borrowing capacity available to borrow					$ 1,000,000
Borrowed					773,778
Lease expense					$ 322,961	$ 297,648
EIDL [Member]
Principal amount		$ 150,000
Interest rate		3.75%
PPP Loan
Principal amount	$ 533,118			$ 533,118			$ 598,567
Term				2 years
Interest rate				1.00%
Extinguishment of debt income	$ 598,567

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Current:
Federal	$ 0	$ 0
State	0	0
Total current	0	0
Deferred:
Federal	228,000	442,000
State	44,000	71,000
Total deferred	272,000	513,000
Valuation allowance	(272,000)	(513,000)
Provision for income taxes	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Expected income tax rate	$ 123,000	$ (42,000)
State income taxes, net of federal tax benefit	23,000	(9,000)
PPP forgiveness	(150,000)	0
Other permanent differences	1,000	10,000
Research credits	(40,000)	(35,000)
Change in valuation allowance	43,000	76,000
Provision for income taxes	$ 0	$ 0

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Other deferred assets	$ 148,000	$ 71,000
Valuation allowance	(148,000)	(71,000)
Current deferred tax assets	0	0
Credits and net operating loss carryforwards	2,151,000	2,222,000
Valuation allowance	(2,151,000)	(2,222,000)
Long-term deferred tax assets	0	0
Total deferred tax assets	0	0
Valuation allowance	0	0
Long-term deferred tax liabilities	0	0
Total deferred tax liabilities	0	0
Net deferred tax assets (liabilities)	$ 0	$ 0

Income Taxes (Details 3)

Income Taxes (Details 3) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Differences in reporting long-term assets	$ 148,000	$ 71,000
Credits and net operating loss carryforwards	2,151,000	2,222,000
Less valuation allowance	(2,299,000)	(2,293,000)
Total deferred tax assets	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Mar. 31, 2021USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryovers	$ 7,100,000
Operating loss carryforward expiration	Mar. 31, 2024
Research and development tax credits	$ 367,000

Major Customers_Suppliers (Deta

Major Customers/Suppliers (Details)	12 Months Ended
	Mar. 31, 2021
Revenue Benchmark [Member]
Major Customers and Suppliers [Line Items]
Concentration percentage	10.00%
Inventory Purchases [Member]
Major Customers and Suppliers [Line Items]
Concentration percentage	47.00%

Related Party Transaction (Deta

Related Party Transaction (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Director [Member]
Related Party Transaction [Line Items]
Consulting fees paid	$ 66,003	$ 69,189